RT Journal Article
T1 Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma
A1 Andrés Guerrero, Vanesa
A1 Perucho González, Lucía
A1 García Feijoo, Julián
A1 Morales Fernández, Laura
A1 Sáenz Francés, Federico
A1 Herrero Vanrell, María Del Rocío
A1 Pablo Júlvez, Luis
A1 Polo Llorens, Vicente
A1 Martínez De La Casa Fernández-Borrella, José María
A1 Konstas, Anastasios Georgios P.
AB The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG). The use of anti-VEGFs for modifying wound healing in glaucoma filtration surgery (GFS) is also reviewed. Selected studies investigating the use of anti-VEGF agents or antimetabolites in GFS or the management of NVG have demonstrated that these agents can improve surgical outcomes. However, anti-VEGF agents have yet to demonstrate specific advantages over the more established agents commonly used today. Further studies are needed to evaluate the duration of action, dosing intervals, and toxicity profile of these treatments.
PB Springer Healthcare
SN 0741-238X
YR 2017
FD 2017-02
LK https://hdl.handle.net/20.500.14352/18063
UL https://hdl.handle.net/20.500.14352/18063
LA eng
NO Andrés Guerrero, V., Perucho González, L., García Feijoo, J. et al. «Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma». Advances in Therapy, vol. 34, n.o 2, febrero de 2017, pp. 378-95. Springer Link, https://doi.org/10.1007/s12325-016-0461-z.
NO To view enhanced content for this article go to: http://www.medengine.com/Redeem/4237F06040074294.
NO Instituto de Investigación Hospital Clínico San Carlos de Madrid
NO OFTARED
NO Grupo de Investigación UCM 920415
NO Ministerio de Economía, Comercio y Empresa (España)
DS Docta Complutense
RD 20 ene 2026